Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 16/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8694185 | 0.98 | SIGMAR1 (0.69) | SIGMAR1HRH3SLC6A3MAOB | |
| SCHEMBL13306955 | 0.98 | SIGMAR1 (0.73) | SIGMAR1HRH3SLC6A3MAOB | |
| SCHEMBL2353465 | 0.90 | SIGMAR1 (0.59) | SIGMAR1HRH3MAOB | |
| Hydrochloric Acid SCHEMBL7255708 | 0.89 | SIGMAR1 (0.58) | SIGMAR1HRH3MAOB | |
| SCHEMBL791606 | 0.85 | SIGMAR1 (0.97) | SIGMAR1SLC6A3 | |
| SCHEMBL12642486 | 0.84 | SIGMAR1 (0.70) | SIGMAR1SLC6A3 | |
| SCHEMBL18772837 | 0.83 | SIGMAR1 (0.74) | SIGMAR1HRH3SLC6A3 | |
| SCHEMBL7332913 | 0.83 | SIGMAR1 (1.00) | SIGMAR1SLC6A3 | |
| SCHEMBL13675505 | 0.83 | SIGMAR1 (0.71) | SIGMAR1 | |
| SCHEMBL19040059 | 0.83 | SIGMAR1 (0.55) | SIGMAR1HRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-0655056-B1 | AZACYCLYL-TERMINATED N-(DIHYDROXY ALKYL)-ETHYNYL-ALANINE AMIDES FOR TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5780494-A | RENIN INHIBITOR | G. D. SEARLE & CO. (US) | 1998-07-14 | — | — | US | disclosed |
| US-5760035-A | PIPERIDINE COMPOUNDS SUBSTITUTED WITH AN AMINOALKYL GROUP AND AN ARYLOXYALKYL GROUP, ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, IMMUNOSUPPRESSANTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-06-02 | — | — | US | disclosed |
| EP-0655056-A1 | PIPERIDINYL-TERMINATED N-(DIHYDROXY ALKYL)-ETHYNYL-ALANINE AMIDES FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5385898-A | Hypertensive agents; cardiovascular disorders; renin inhibitors; glaucoma | G.D. SEARLE & CO. (US) | 1995-01-31 | — | — | US | disclosed |
| US-5304552-A | Renin inhibitors | G.D. SEARLE & CO. (US) | 1994-04-19 | — | — | US | disclosed |
| WO-1994004495-A1 | PIPERIDINYL-TERMINATED N-(DIHYDROXY ALKYL)-ETHYNYL-ALANINE AMIDES FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5212185-A | Enzyme inhibitors | G. D. SEARLE & CO. (US) | 1993-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | SIGMAR1 3155/4885HRH3 4130/4885SLC6A3 2991/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | SIGMAR1 3155/4885HRH3 4130/4885SLC6A3 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.